Six years without pholcodine; Norwegians are significantly less IgE-sensitized and clinically more tolerant to neuromuscular blocking agents

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 72, Issue 5, 2017, Pages 813-819

  de Pater, G H ^a   Florvaag, E ^a,b   Johansson, S G O ^c,d   Irgens, A ^a   Petersen, M N H ^a   Guttormsen, A B ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

anaesthesia; anaphylaxis; IgE antibodies; pholcodine

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; NEUROMUSCULAR BLOCKING AGENT; PHOLCODINE; ROCURONIUM; SUXAMETHONIUM; CODEINE; MORPHOLINE DERIVATIVE;

ANAPHYLAXIS; ARTICLE; DEATH; DISEASE SEVERITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MARKET; PREVALENCE; PRIORITY JOURNAL; SENSITIZATION; ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; CHILD; DRUG HYPERSENSITIVITY; DRUG RECALL; FEMALE; HEALTH SURVEY; IMMUNOLOGY; MALE; MIDDLE AGED; NORWAY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; CHILD; CODEINE; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; MORPHOLINES; NEUROMUSCULAR BLOCKING AGENTS; NORWAY; POPULATION SURVEILLANCE; PREVALENCE; SAFETY-BASED DRUG WITHDRAWALS; YOUNG ADULT;

EID: 85016958670     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.13081     Document Type: Article

References (27)

1. Mertes PM, Aimone-Gastin I, Gueant-Rodriguez RM, Mouton-Faivre C, Audibert G, O'Brien J et al. Hypersensitivity reactions to neuromuscular blocking agents. Curr Pharm Des 2008;14:2809–2825.
2. Kroigaard M, Garvey LH, Gillberg L, Johansson SG, Mosbech H, Florvaag E et al. Scandinavian Clinical Practice Guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia. Acta Anaesthesiol Scand 2007;51:655–670.
3. Mertes PM, Laxenaire MC. Allergy and anaphylaxis in anaesthesia. Minerva Anestesiol 2004;70:285–291.
4. Harper NJ, Dixon T, Dugue P, Edgar DM, Fay A, Gooi HC et al. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia 2009;64:199–211.
5. Harboe T, Guttormsen AB, Irgens A, Dybendal T, Florvaag E. Anaphylaxis during anesthesia in Norway: a 6-year single-center follow-up study. Anesthesiology 2005;102:897–903.
6. Reitter M, Petitpain N, Latarche C, Cottin J, Massy N, Demoly P et al. French Network of Regional Pharmacovigilance Centres. Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis. Allergy 2014;69:954–959.
7. Axon AD, Hunter JM. Editorial III: Anaphylaxis and anaesthesia – all clear now? Br J Anaesthesia 2004;93:501–504.
8. Mertes PM, Laxenaire MC. Anaphylaxis during general anaesthesia – prevention and management. CNS Drugs 2000;14:115–133.
9. Johansson SGO, Oman H, Degerbeck F, Tunelli J, Florvaag E, Nopp A. Anaphylaxis to atracurium – a non-QAI-dependent reaction? Acta Anaesthesiol Scand 2012;56:262–263.
10. Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. Nature 1983;306:262–264.
11. Florvaag E, Johansson SGO, Oman H, Venemalm L, Degerbeck F, Dybendal T et al. Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively. Acta Anaesthesiol Scand 2005;49:437–444.
12. Florvaag E, Johansson SGO. The pholcodine story. Immunol Allergy Clin North Am 2009;29:419–427.
13. Florvaag E, Johansson SGO, Oman H, Harboe T, Nopp A. Pholcodine stimulates a dramatic increase of IgE in IgE-sensitized individuals. A pilot study. Allergy 2006;61:49–55.
14. Harboe T, Johansson SG, Florvaag E, Oman H. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. Allergy 2007;62:1445–1450.
15. Johansson SGO, Oman H, Nopp A, Florvaag E. Pholcodine caused anaphylaxis in Sweden 30 years ago. Allergy 2009;64:820–821.
16. Johansson SGO, Florvaag E, Oman H, Poulsen LK, Mertes PM, Harper NJ et al. National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study. Allergy 2010;65:498–502.
17. Katelaris CH, Kurosawa M, Moon HB, Borres M, Florvaag E, Johansson SG. Pholcodine consumption and immunoglobulin E-sensitization in atopics from Australia, Korea, and Japan. Asia Pac Allergy 2014;4:86–90.
18. Dong S, Acouetey DS, Guéant-Rodriguez RM, Zmirou-Navier D, Rémen T, Blanca M et al. Prevalence of IgE against neuromuscular blocking agents in hairdressers and bakers. Clin Exp Allergy 2013;43:1256–1262.
19. Florvaag E, Johansson SGO, Irgens A, de Pater GH. IgE-sensitization to the cough suppressant pholcodine and the effects of its withdrawal from the Norwegian market. Allergy 2011;66:955–960.
20. Guttormsen AB, Harboe T, Florvaag E. Allergic reactions during anesthesia – a national network for registration, diagnosis and follow-up. Tidsskr Nor Laegeforen 2000;120:127.
21. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977;1:466–469.
22. IBM Corp. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp; Released 2013.
23. Garvey LH, Roed-Petersen J, Menné T, Husum B. Danish Anaesthesia Allergy Centre – preliminary results. Acta Anaesthesiol Scand 2001;45:1204–1209.
24. EMA/890819. Questions and answers on the review of the marketing authorisations for medicines containing pholcodine. www.ema.europa.eu, 2011.
25. Florvaag E, Johansson SG. The pholcodine case. Cough medicines, IgE-sensitization, and anaphylaxis: a devious connection. World Allergy Organ J 2012;5:73–78.
26. Moneret-Vautrin DA, Morisset M, Flabbee J, Beaudouin E, Kanny G. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 2005;60:443–451.
27. Dong SW, Mertes PM, Petitpain N, Hasdenteufel F, Malinovsky JM. Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005–2007). Minerva Anestesiol 2012;78:868–878.